Mind Medicine or MindMed Inc. is a US-based psychedelic medicine company that works on treating mental health disorders. This article gives you a complete overview of this company as well as its stock and then discusses the MNMD stock forecast from 2025 to 2040.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)
MindMed Inc. was established in 2010 and the current CEO of this company is Robert Barrow. The headquarters of MindMed is in New York (United States of America).
Mind medicine is working for the solution of mental patients through its panacea medicine and therapy the flagship project of this company is research and digital medicine.
| Mind Medicine (MindMed) Inc Overview | |
| Details | Information |
| Stock Name | Mind Medicine (MindMed) Inc |
| Stock Symbol | MNMD |
| Stock Exchange | NASDAQ |
| Market Cap | 518.45M USD |
| Founder | Robert Barrow |
| Founded Year | 14 Dec 2021 |
| Headquarter | One World Trade Center, Suite 8500, New York, NY 10007 |
Fundamentals Chart of the MNMD Stock
The average volume of this share is 1.21M and the return on equity is -54.61%. Earning per share of this stock is -1.71 and the total equity is $150 M.
| Stock Static | Data |
| AVG Volume | 1.21M |
| Revenue Growth % (Yearly) | – |
| Net Income | -$74M |
| ROE | -54.61% |
| EPS | -1.71 |
| P/B Ratio | – |
| P/E Ratio | – |
| Dividend Yield | – |
| Total Equity | $150 M |
| Net profit margin | 0% |
| EBITDA Margin | -$91M |
| Effective Tax Rate | – |
MNMD Stock Price History Table
MNMD stock was listed on the NASDAQ stock exchange on 6 March 2020 and started from 6$ per share but after the 1 year of the listing, this stock touched its historical price and reached $60 per share.
After the year 2021, this stock continuously touched the lower circuit and hit $2.64 on 6 Jan 2023. The 52-week high price of this stock is $12.22 per share.
| Time | Per Share Value (USD) |
| Previous close | $8.11 |
| Day Range | $6.93 – $8.09 |
| Before 5D | $7.04 |
| Before 1M | $7.29 |
| Before 6M | $7.10 |
| Before 1Y | $4.20 |
| 52 Week Range | $3.50 – $12.22 |
| 6 March 2020 | $6.00 |
| All time Max | $68.55 |
| All time Lowest | $0.015 |
| Starting Price | $39.00 |
Major Shareholders of the MNMD Stock
Commodore Capital LP holds 10.91% of this stock which is the largest share holder of this stock and the second largest share holder of this stock is Deep Track Capital LP which holds 9.63% shares of this stock.
| Shareholder | Shares % |
|---|---|
| Commodore Capital LP | 10.91% |
| Deep Track Capital LP | 9.63% |
| BlackRock Advisors LLC | 7.40% |
| Blackstone Alternative Asset Management LP | 5.33% |
| Driehaus Capital Management LLC | 5.31% |
Upcoming 1 to 10-Year MNMD Stock Forecast Price Chart
MNMD stock forecast for the upcoming 10 years is presented in the table below you can see the data and take an idea for the knowledge prospective or investment.
| Year | Minimum Per Stock Value | Maximum Per Stock Value |
| 1 Year | $7.15 | $9.84 |
| 2 Year | $8.19 | $9.25 |
| 3 Year | $7.14 | $8.23 |
| 4 Year | $8.14 | $10.19 |
| 5 Year | $9.34 | $10.84 |
| 6 Year | $10.28 | $12.72 |
| 7 Year | $11.28 | $13.09 |
| 8 Year | $12.08 | $14.18 |
| 9 Year | $13.87 | $15.04 |
| 10 Year | $14.08 | $16.78 |
MNMD Stock Forecast 2025
MNMD stock forecast for 2025 depends on the growth of the psychedelic medicine industry and experts expect that this industry grow by 20%. So the share price of MNMD can also grow and expected that MNMD stock will touch $9.84 per share.
| Year | Minimum Per Stock Price | Maximum per Stock Price |
| 2025 | $7.15 | $9.84 |
MNMD Stock Forecast 2026
MNMD continuously invests in developing new products and smart solutions so the stock price prediction of MNMD for the year 2026 is estimated to be $9.25 per share.
| Year | Minimum Per Stock Price | Maximum per Stock Price |
| 2026 | $8.19 | $9.25 |
MNMD Stock Forecast 2027
MNMD stock price forecast for 2027 is expected to the $7.14 at the start of the year and this price will touch $8.23 at the end of the year.
| Year | Minimum Per Stock Price | Maximum per Stock Price |
| 2027 | $7.14 | $8.23 |
MNMD Stock Forecast 2030
MindMed Inc. will jump into artificial intelligence and make better products with a good interface so the MNMD stock forecast for 2030 is expected to the $10.28 to $12.72 per share.
| Year | Minimum Per Stock Price | Maximum per Stock Price |
| 2030 | $10.28 | $12.72 |
Mind Medicine Stock Forecast 2025 To 2030 Price Table
Mind Medicine stock forecast for the year 2025 is $7.15 to $9.84 per share and according to the favorable condition of the market, this stock will hit $36.48 to $39.43 per share in 2040.
| Year | Minimum Per Stock Value | Maximum Per Stock Value |
| 2025 | $7.15 | $9.84 |
| 2026 | $8.19 | $9.25 |
| 2027 | $7.14 | $8.23 |
| 2028 | $8.14 | $10.19 |
| 2029 | $9.34 | $10.84 |
| 2030 | $10.28 | $12.72 |
| 2031 | $11.28 | $13.09 |
| 2032 | $12.08 | $14.18 |
| 2033 | $13.87 | $15.04 |
| 2034 | $14.08 | $16.78 |
| 2035 | $15.81 | $22.49 |
| 2040 | $36.48 | $39.43 |
Risks and Challenges MNMD Stock
Regulatory delays: This is the biggest challenge for the growth of MNMD stock because if the products are not launched at the right time due to delays in the regulatory then the product not perform much as previously.
Market Competition: If the competition is high then the stock price of MMD is facing a down term in the stock market.
Key Drivers Of The MNMD Stock Growth
Industry growth: The psychedelic medicine industry is expected to grow and MindMed Inc. already has adopted this industry so this directly impacts the stock price of MNMD.
Regulatory development: Regulatory developments are also impacting the entire industry of medicine regulatory approval plays a vital role in the development of MindMed treatment.
R&D Advancement: Continuously research and development for the innovation of Mind Medicine Inc. can grow its share price.
Market competition: Many competitors are also sitting in this industry which is high competition.
Microeconomic Conditions: Economic factors like inflation and interest rates also impact the share price of MNMD stock.
Checkout: DraftKings Stock (DKNG) Forecast From 2025 to 2035
Last word of this article
The journey of Mind Medicine (MNMD) stock from 2025 to 2040 is risky for investment because of competition and other factors that are explained in the risk section. But MNMD stock has kept the potential the tackle this risk and innovate its solution from time to time.
After a detailed self-analysis, you can go with a small amount for long-term investments.
FAQs
Is MNMD a good stock to buy?
Yes, you can say this stock is okay for long-term investments.
What does MindMed do?
Mind medicine is working for the solution of mental patients through its panacea medicine and therapy the flagship project of this company is research and digital medicine.
Will MNMD face competition in the psychedelic industry?
Yes, MNMD stock faces high competition from COMPASS Pathways, ATAI Life Sciences (ATAI) and Cybin Inc. (CYBN).